Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 289 of 1,261
  1. US 11219633

    Nucleobase analogue derivatives and their applications

    The Board of Regents of the University of Texas System · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  2. US 11219621

    Methods for treating immunodeficiency disease

    X4 Pharmaceuticals, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  3. US 11219631

    Foamable compositions, breakable foams and their uses

    Vyne Pharmaceuticals Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  4. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  5. US 11219626

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  6. US 11219552

    Intraocular filter device and methods of using same

    The Regents of the University of Colorado, a Body Corporate · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  7. US 11219604

    Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

    Eupraxia Pharmaceuticals USA LLC · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  8. US 11220670

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  9. US 11220486

    Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  10. US 11220509

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  11. US 11220501

    Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor

    Revolution Medicines, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  12. US 11219697

    Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration

    The Regents of the University of California · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  13. US 11219695

    Methods and compositions for the treatment of Fabry disease

    Sangamo Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  14. US 11220575

    Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

    Nektar Therapeutics · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  15. US 11220488

    Crystalline polymorph of Ponesimod

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  16. US 11220477

    Modulators of the eIF2alpha pathway

    The Regents of the University of California · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  17. US 11219636

    Compositions and methods for treating cancer

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  18. US 11219643

    Compositions for cellular restoration and methods of making and using same

    Advanced ReGen Medical Technologies, LLC · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted
  19. US 11213513

    Compositions and methods for promoting hair growth with Mpc1 inhibitors

    The Regents of the University of California · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  20. US 11214569

    Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof

    Lenz Therapeutics, Inc. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  21. US 11214565

    Compound, compositions, and methods

    DENALI THERAPEUTICS INC. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  22. US 11213592

    Antibody-sting agonist conjugates and their use in immunotherapy

    The Board of Regents of the University of Texas System · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  23. US 11213549

    Compositions and method for treating primary sclerosing cholangitis and related disorders

    Finch Therapeutics Holdings LLC · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  24. US 11213529

    Salt of substituted urea derivative and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.